Bio4t2 Doses First Patient with BT-001-Targeting CAR-T Therapy B4t2-001 Developed via PrismCore™ Platform

SantiagoJanuary 11, 2023PR Newswire -- Bio4t2 administered T cells containing chimeric antigen receptors (CAR) to the first patient, targeting the overexpression of BT-001 antigen found in various types of solid tumors. The CAR-T (B4t2-001) was developed using Bio4t2's PrismCore.^™Platform Development.

"This first-in-human study marks the initial evaluation of a therapy based on Bio4t2 technology," said Laurence Cooper, M.D., Ph.D., Executive Chairman of the Board. "PrismCore enables the rapid generation of CAR-T cells that can safely target self-antigens, opening new frontiers for delivering CAR-T therapies to treat various types of solid tumors," added Dr. Cooper. "This clinical trial is at the cutting edge of CAR-T biology, offering a pathway to treat a large number of patients worldwide suffering from aggressive cancers."

"We are excited to begin the first clinical trial of our CAR-T therapy targeting BT-001, a novel antigen for this therapy," said Dr. Farzad Haerizadeh, Chief Scientific Officer and Co-founder. "Our CAR-T is calibrated through PrismCore to distinguish BT-001 levels on tumors from those on healthy cells. In fact, B4t2-001 has demonstrated effective anti-tumor activity and long-term protective capabilities in preclinical studies in rodents and non-human primates with a strong safety profile. This trial will help validate the platform, enabling the development of safe and effective CAR-T therapies for various types of solid tumors," Haerizadeh stated.

AboutClinical Trial 

Phase 1 Investigator-Initiated Study (clinicaltrials.govNCT05621486) for evaluating the B4t2-001 dose escalation in patients with solid tumors. This trial is being conducted at Shanghai East Hospital and Shanghai Artron Hospital, assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of autologous CAR-T as a single agent in adult subjects following lymphodepletion treatment.